Welcome to our dedicated page for Ardelyx SEC filings (Ticker: ARDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ardelyx, Inc. filings document a commercial-stage biopharmaceutical company with U.S. product revenue from IBSRELA and XPHOZAH and development activity centered on tenapanor and NHE3 inhibition. Form 8-K reports cover quarterly operating results, preliminary product sales, cash and investment updates, Regulation FD presentation materials, and other material-event disclosures tied to the company’s commercial and clinical programs.
Ardelyx proxy materials describe annual meeting proposals, director elections, say-on-pay matters, auditor ratification, executive compensation, board structure, and stockholder voting mechanics. Additional current reports record officer appointments, executive transitions, transition and separation agreements, compensatory arrangements, governance matters, and disclosure controls relevant to the company’s public-company reporting obligations.
ARDELYX, INC. officer Joseph James Reilly reported selling a total of 3,719 shares of common stock at an average price of $6.2675 per share. According to the footnotes, these sales were automatic sell-to-cover transactions triggered by the vesting of restricted stock units and were made solely to cover withholding taxes. After the sales, he directly holds 149,107 shares of Ardelyx common stock. The holdings include 1,765 shares acquired under the company’s employee stock purchase plan on February 27, 2026.
Ardelyx, Inc. Chief Financial Officer Susan Hohenleitner reported a small tax-related share sale. She disposed of 1,455 shares of common stock on May 21, 2026 at an average price of $6.2675 per share. A footnote explains the transaction was an automatic sell-to-cover triggered by the vesting of restricted stock units, with shares sold solely to cover applicable withholding taxes rather than as a discretionary open-market sale. After this transaction, she directly holds 229,078 Ardelyx common shares.
ARDELYX, INC. officer John E. Bishop reported a small sale of common stock tied to restricted stock unit (RSU) vesting. He disposed of 2,306 shares at an average price of $6.2675 per share, and held 336,845 shares afterward.
According to the footnote, the transaction was an automatic sell-to-cover required by the original RSU grant terms, with shares sold solely to pay applicable withholding taxes. This indicates a routine, compensation-related tax event rather than a discretionary open-market sale based on a view of the stock.
ARDELYX, INC. reported that Chief Human Resources Officer Brady James Parker had 1,846 shares of common stock sold at an average price of $6.2675 per share. According to the footnote, this automatic sell-to-cover transaction occurred upon RSU vesting to satisfy withholding taxes, leaving him with 261,066 shares directly owned.
ARDELYX, INC. Chief Commercial Officer Eric Duane Foster reported sales of 7,998 shares of common stock on May 21, 2026 at a price of $6.2675 per share.
According to the footnote, these trades were an automatic sell-to-cover tied to vested restricted stock units and were executed solely to cover applicable withholding taxes rather than as discretionary open-market sales.
ARDELYX, INC. Chief Business Officer Mike Kelliher reported selling a total of 7,248 shares of common stock on May 21, 2026 at a price of $6.2675 per share in three separate transactions. A footnote explains these sales were an automatic sell-to-cover triggered by the vesting of restricted stock units, with shares sold solely to cover applicable withholding taxes. This indicates the activity was a tax-related mechanism tied to equity compensation rather than a discretionary reduction of his investment in the company.
Ardelyx, Inc. Chief Patient Officer Laura A. Williams reported multiple open-market sales totaling 6,989 shares of common stock at $6.2675 per share. According to the footnote, these transactions were automatic sell-to-cover trades tied to RSU vesting, executed solely to pay withholding taxes. Williams continued to hold 434,579 shares directly after the transactions.
ARDELYX, INC. President & CEO Michael Raab reported routine sales of company common stock tied to restricted stock unit (RSU) vesting. On May 21, 2026, entities associated with him sold a total of 54,748 shares of Ardelyx common stock at $6.2675 per share.
According to the disclosure, these transactions were an automatic sell-to-cover required by the original RSU grant terms, and the shares were sold solely to cover applicable withholding taxes at vesting. After these sales, Raab directly held about 1,759,848 common shares, with additional indirect holdings of 1,000 shares and 24,364 shares held in family-related trusts.
ARDX submitted a Rule 144 notice relating to Common Stock tied to the vesting of 24,986 restricted stock units on 05/19/2026. The filing also lists three dispositions by Mike Kelliher on 02/20/2026 of 8,434, 1,159 and 2 shares with reported proceeds of $49,465.41, $6,622.29 and $11.41, respectively.
ARDX Form 144 filing records vesting-related sale activity. 5,355 restricted stock units vested on 05/19/2026 and are listed as securities to be sold. The filing also shows prior dispositions on 02/20/2026 of 1,786 shares for $10,474.89 and 247 shares for $1,411.31.